mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
Status:
RECRUITING
Trial end date:
2028-01-11
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the effectiveness and safety of mFOLFOX7Oxaliplatin,Calcium Levofolinate,Fluorouracil combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
The primary outcome measure is to evaluate the primary pathological response (MPR) rate of the therapy for Hepatocellular Carcinoma.
The secondary Outcome measures include the objective response rate (ORR), the duration of response (DOR), disease control rate (DCR), progression-free survival rate (PFSR) \[ Time Frame: 6- and 12-month\], overall survival rate (OSR) \[ Time Frame: 6- and 12-month\], the median progression-free survival time (mPFS) and median overall survival time (mOS) of the therapy for Hepatocellular Carcinoma.
Moreover, this study aims to assess the safety and tolerability of the Therapy for Hepatocellular Carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University